Medical Marijuana Inc (OTCMKTS:MJNA) reported that Mexico’s government granted 22 additional import permits for RSHO-X™. This development expands the firm’s base into a market estimated to reach $10 billion – 12 billion yearly.
The highlights
Earlier in February, the Mexican government released two of the nation’s first licenses to import Medical Marijuana’s cannabidiol item RSHO-X™ into the nation. This step was taken to help 2 children suffering from epilepsy. Now, the Mexico government has allowed 22 additional permits to cure mostly adolescents in the nation suffering from epilepsy.
The distributor HempMeds® Mexico has worked with RSHO-X advocate, Mr. Raul Elizalde, on the project. Their mutual initiatives have led to major changes in country’s marijuana policy, as President, Pena Nieto, reported in April, his intent to move the nation away from marijuana ban and towards regulation and prevention, including medicinal use.
The plans
Dr. Stuart Titus, the CEO, said that with over 120 million citizens, Mexico demonstrates a potentially vast market for company. Medical Marijuana’s objective is ‘access for all’ and they have already made considerable strides in nation to get their products to the residents there suffering with unbearable medical problems. As the message continues to spread regarding the promising results that families are getting from company’s products, they project demand to increase throughout the nation.
The marijuana reform bill proposed by Nieto, which approves the use and imports of medications made with marijuana, was sanctioned by the Mexican Senate in June. Recently, it has been deferred for a new poll until September 2016 after legislators complete changes in the original bill.
The CEO of Medical Marijuana said that despite the pause on a deal from Mexico legislators, the company and its associates in Mexico, will continue to fight for residents to expand and get legal access to medical pot for the needy people.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) Gets $8 Million Grant From Horizon 2020 Program
Pluristem Therapeutics Inc. (NASDAQ:PSTI) has received a grant of $8 million from its critical limb ischemia program. This grant is part of the EU’s largest innovation and research program, “Horizon 2020”.
The Phase III trial of PLX-PAD in critical limb ischemia will be a collaborative assignment carried out by a global consortium driven by the BCRT. It will be performed under the leadership of Professor Hans-Dieter Volk and Professor Petra Reinke together with company.
The consortium will undertake a scientific program along with the trial, utilizing in-depth endocrine, immunological, and molecular studies to better understand the process of PLX-PAD action in CLI.
Pluristem’s PLX-PAD program has been chosen for the EU’s Adaptive Pathways task. It has an objective to lessen the time it requires for innovative medicines to reach subjects with serious conditions. Zami Aberman, the CEO and Chairman, said that they felt honored to have received this grant designed to help the planned commercialization of its lead candidate.
